An immediate hemolytic reaction induced by repeated administration of oxaliplatinCHEN, Vivien M. Y; THRIFT, Karen M; MOREL-KOPP, Marie-Christine et al.Transfusion (Philadelphia, PA). 2004, Vol 44, Num 6, pp 838-843, issn 0041-1132, 6 p.Article

Longitudinal assessment of oxaliplatin-induced neuropathyBURAKGAZI, A. Z; MESSERSMITH, W; VAIDYA, D et al.Neurology. 2011, Vol 77, Num 10, pp 980-986, issn 0028-3878, 7 p.Article

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathyPARK, Susanna B; LIN, Cindy S.-Y; KRISHNAN, Arun V et al.Brain. 2009, Vol 132, pp 2712-2723, issn 0006-8950, 12 p., 10Article

Oxaliplatin-induced immune pancytopeniaTALEGHANI, Behrouz Mansouri; FONTANA, Stefano; MEYER, Oliver et al.Transfusion (Philadelphia, PA). 2005, Vol 45, Num 5, pp 704-708, issn 0041-1132, 5 p.Article

Efficacy of IT oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathyARGYRIOU, A. A; CHRONI, E; POLYCHRONOPOULOS, P et al.Neurology. 2006, Vol 67, Num 12, pp 2253-2255, issn 0028-3878, 3 p.Article

Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug-induced nonimmunologic protein adsorptionARNDT, Patricia; GARRATTY, George; ISAAK, Edahn et al.Transfusion (Philadelphia, PA). 2009, Vol 49, Num 4, pp 711-718, issn 0041-1132, 8 p.Article

Reversible Posterior Leukoencephalopathy Syndrome Associated With OxaliplatinPINEDO, Daryl M; SHAH-KHAN, Farheen; SHAH, Prabodh C et al.Journal of clinical oncology. 2007, Vol 25, Num 33, pp 5320-5321, issn 0732-183X, 2 p.Article

Antibodies to oxaliplatin, a chemotherapeutic, are found in plasma of healthy blood donorsLEGER, Regina M; GARRATTY, George.Transfusion (Philadelphia, PA). 2011, Vol 51, Num 8, pp 1740-1744, issn 0041-1132, 5 p.Article

Protection against oxaliplatin-induced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocyclineBOYETTE-DAVIS, J; DOUGHERTY, P. M.Experimental neurology (Print). 2011, Vol 229, Num 2, pp 353-357, issn 0014-4886, 5 p.Article

The influence of the temperature of the dialysate on hyperglycemia during Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with OxaliplatinVANEESTER, J; WYFFELS, P. A. H; VAN LIMMEN, J. G. M et al.Acta anaesthesiologica belgica. 2011, Vol 62, Num 2, issn 0001-5164, p. 126Conference Paper

Immune-mediated pancytopenia induced by oxaliplatin: a case reportFONTAO-WENDEL, Rita; HOFF, Paulo M; LAZAR, Arlette et al.Transfusion (Philadelphia, PA). 2010, Vol 50, Num 7, pp 1453-1459, issn 0041-1132, 7 p., 1Article

Organic cation transporters are determinants of oxaliplatin cytotoxicitySHUZHONG ZHANG; LOVEJOY, Katherine S; LIPPARD, Stephen J et al.Cancer research (Baltimore). 2006, Vol 66, Num 17, pp 8847-8857, issn 0008-5472, 11 p.Article

Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor propertiesGHIRARDI, Orlando; LO GIUDICE, Pietro; ZANNA, Claudio et al.Anticancer research. 2005, Vol 25, Num 4, pp 2681-2687, issn 0250-7005, 7 p.Article

Oxaliplatin-induced immune mediated thrombocytopeniaBEG, Muhammad S; KOMROKJI, Rami S; AHMED, Kashif et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 5, pp 925-927, issn 0344-5704, 3 p.Article

Oxaliplatin-related neurotoxicity : How and why?PASETTO, Lara Maria; D'ANDREA, Mario Rosario; ROSSI, Elena et al.Critical reviews in oncology/hematology. 2006, Vol 59, Num 2, pp 159-168, issn 1040-8428, 10 p.Article

Oxaliplatin and axonal Na⁺ channel function in vivoKRISHNAN, Arun V; GOLDSTEIN, David; FRIEDLANDER, Michael et al.Clinical cancer research. 2006, Vol 12, Num 15, pp 4481-4484, issn 1078-0432, 4 p.Article

Clinical pharmacokinetics of oxaliplatin : A critical reviewGRAHAM, M. A; LOCKWOOD, G. F; GREENSLADE, D et al.Clinical cancer research. 2000, Vol 6, Num 4, pp 1205-1218, issn 1078-0432Article

Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced NeurotoxicityPARK, Susanna B; GOLDSTEIN, David; LIN, Cindy S.-Y et al.Journal of clinical oncology. 2009, Vol 27, Num 8, pp 1243-1249, issn 0732-183X, 7 p.Article

Predictive Factors of Oxaliplatin Neurotoxicity : The Involvement of the Oxalate Outcome PathwayGAMELIN, Laurence; CAPITAIN, Olivier; MOREL, Alain et al.Clinical cancer research. 2007, Vol 13, Num 21, pp 6359-6368, issn 1078-0432, 10 p.Article

Hypersensitivity reactions to oxaliplatin : experience in a single instituteSIU, S. W. K; CHAN, R. T. T; AU, G. K. H et al.Annals of oncology. 2006, Vol 17, Num 2, pp 259-261, issn 0923-7534, 3 p.Article

Oxaliplatine dans les cancers digestifs = Oxaliplatin in digestive cancerLa Lettre du cancérologue (Boulogne). 2004, Vol 13, Num 5, pp 4-13, issn 1165-113X, 10 p., SUP1Conference Paper

A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancerYEE CHAO; HSIEH, Jan-Sing; LI, Chung-Pin et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 4, pp 799-806, issn 0344-5704, 8 p.Article

Overexpression of the Circadian Clock Gene Bmal1 Increases Sensitivity to Oxaliplatin in Colorectal CancerZENG, Zhao-Lei; LUO, Hui-Yan; JING YANG et al.Clinical cancer research (Print). 2014, Vol 20, Num 4, pp 1042-1052, issn 1078-0432, 11 p.Article

Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance)LOPRINZI, Charles L; RUI QIN; DAKHIL, Shaker R et al.Journal of clinical oncology. 2014, Vol 32, Num 10, pp 997-1005, issn 0732-183X, 9 p.Article

RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapyALONSO-ESPINACO, Virginia; CUATRECASAS, Miriam; JARES, Pedro et al.European journal of cancer (1990). 2014, Vol 50, Num 11, pp 1973-1981, issn 0959-8049, 9 p.Article